LU93169I2 - Lésinurad , ou un sel pharmaceutiquement acceptable de celui-ci - Google Patents

Lésinurad , ou un sel pharmaceutiquement acceptable de celui-ci Download PDF

Info

Publication number
LU93169I2
LU93169I2 LU93169C LU93169C LU93169I2 LU 93169 I2 LU93169 I2 LU 93169I2 LU 93169 C LU93169 C LU 93169C LU 93169 C LU93169 C LU 93169C LU 93169 I2 LU93169 I2 LU 93169I2
Authority
LU
Luxembourg
Prior art keywords
lésinurad
pharmaceutically acceptable
acceptable salt
hiv
mercaptoacetanilides
Prior art date
Application number
LU93169C
Other languages
English (en)
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of LU93169I2 publication Critical patent/LU93169I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Road Signs Or Road Markings (AREA)
  • Pens And Brushes (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
LU93169C 2004-08-25 2016-08-10 Lésinurad , ou un sel pharmaceutiquement acceptable de celui-ci LU93169I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60422004P 2004-08-25 2004-08-25
US60421904P 2004-08-25 2004-08-25
US68635105P 2005-05-31 2005-05-31
EP05790722A EP1789039B1 (fr) 2004-08-25 2005-08-25 S-triazolyl alpha-mercaptoacetanildes tenant lieu d'inhibiteurs de la transcriptase inverse vih

Publications (1)

Publication Number Publication Date
LU93169I2 true LU93169I2 (fr) 2016-10-10

Family

ID=36000576

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93169C LU93169I2 (fr) 2004-08-25 2016-08-10 Lésinurad , ou un sel pharmaceutiquement acceptable de celui-ci

Country Status (32)

Country Link
US (8) US7947721B2 (fr)
EP (5) EP2433633A1 (fr)
JP (2) JP4952943B2 (fr)
KR (1) KR101241716B1 (fr)
CN (2) CN101083987B (fr)
AT (2) ATE540677T1 (fr)
AU (2) AU2005280130C9 (fr)
BR (2) BRPI0514630B8 (fr)
CA (1) CA2578068C (fr)
CY (2) CY1112221T1 (fr)
DK (1) DK2135608T3 (fr)
EA (2) EA015846B1 (fr)
EC (1) ECSP077322A (fr)
ES (2) ES2380604T3 (fr)
FR (1) FR16C0031I2 (fr)
HK (1) HK1133582A1 (fr)
HR (1) HRP20130075T1 (fr)
HU (1) HUS1600034I1 (fr)
IL (3) IL181523A (fr)
IN (1) IN2014CN03762A (fr)
LT (1) LTC2135608I2 (fr)
LU (1) LU93169I2 (fr)
ME (1) ME01512B (fr)
MX (1) MX2007002236A (fr)
NL (1) NL300825I2 (fr)
NZ (2) NZ581376A (fr)
PL (1) PL2135608T3 (fr)
PT (1) PT2135608E (fr)
RS (1) RS52632B (fr)
SG (2) SG155246A1 (fr)
SI (1) SI2135608T1 (fr)
WO (1) WO2006026356A2 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015846B1 (ru) * 2004-08-25 2011-12-30 Ардеа Байосайенсиз, Инк. 2-[5-бром-4-(4-циклопропилнафталин-1-ил)-4н-[1,2,4]триазол-3-илсульфанил]уксусная кислота и ее метиловый эфир
WO2007050087A1 (fr) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. Acides N[S(4-aryltriazol-3-yl)α-mercaptoacétyl]-p-aminobenzoïques EN TANT QU'INHIBITEURS DE TRANSCRIPTASE INVERSE DE VIH
KR101542629B1 (ko) 2007-05-30 2015-08-06 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 억제제
WO2009030996A1 (fr) * 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Composés triazole utilisés comme agonistes du récepteur de type toll (tlr)
NZ601774A (en) * 2007-11-27 2013-07-26 Ardea Biosciences Inc Substituted diazole and triazole compounds and compositions and methods of use
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
AU2009289647C1 (en) * 2008-09-04 2013-03-21 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
AR073964A1 (es) * 2008-10-24 2010-12-15 Ardea Biosciences Inc Composiciones que comprenden acido 4-(2-(5-bromo-4-(1-ciclopropilnaftalen -4-il) -4h- 1,2,4-triazol-3-il tio ) acetamido)-3-clorobenzoico y sus sales farmaceuticamente aceptables y metodos de preparacion y uso delos mismos
WO2010048592A1 (fr) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprenant l'acide 4-(2-(5-bromo-4-(1- cyclopropylnaphtalén-4-yl)-4h-1,2,4-triazol-3-ylthio)acétamido-3- chlorobenzoïque et ses sels de qualité pharmaceutique
EP2432468A2 (fr) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Procédés pour moduler des taux d'acide urique
CN102040546B (zh) * 2009-10-10 2014-10-15 台州市华南医化有限公司 一种4-环丙基-1-异硫氰基萘的制备方法及中间体4-环丙基-1-萘甲醛肟/卤化物
NZ600984A (en) * 2010-01-08 2013-10-25 Ardea Biosciences Inc Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
WO2011126852A2 (fr) 2010-03-30 2011-10-13 Ardea Biosciences, Inc. Traitement de la goutte
CA2802407C (fr) 2010-06-15 2018-01-23 Ardea Biosciences, Inc. Traitement de la goutte et de l'hyperuricemie
US9212135B2 (en) 2010-06-16 2015-12-15 Ardea Biosciences, Inc. Phenylthioacetate compounds, compositions and methods of use
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
CN101899013B (zh) * 2010-07-12 2012-07-25 山东大学 2-(2-取代芳基-2h-1,2,4-三唑-3-巯基)乙酰胺衍生物及其制备方法与应用
CN103249417A (zh) * 2010-10-15 2013-08-14 阿迪亚生命科学公司 用于治疗高尿酸血症及相关疾病的方法
DK2658846T3 (en) 2010-12-30 2017-02-13 Ardea Biosciences Inc POLYMORPHE FORMS OF 2- (5-BROMO-4- (4-CYCLOPROPYLNAPHTHALEN-1-YL) -4H-1,2,4-TRIAZOL-3-YLTHIO) ACETIC ACID AND APPLICATIONS THEREOF
KR101988066B1 (ko) 2011-11-03 2019-09-27 아디아 바이오사이언스즈 인크. 3,4-이치환된 피리딘 화합물, 이의 사용 방법 및 이를 포함하는 조성물
AR091651A1 (es) * 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
CN105263913B (zh) * 2013-06-14 2017-12-15 广东东阳光药业有限公司 硫代1,2,4‑三唑衍生物及其制备方法
CN103524440B (zh) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
EP3071554B1 (fr) * 2013-11-22 2018-10-03 Crystal Pharmatech Co., Ltd. Formes cristallines de lésinurad
CN104557748A (zh) * 2014-01-25 2015-04-29 广东东阳光药业有限公司 硫代-1,2,4-三唑衍生物的新的固体形态
CN105315218A (zh) * 2014-07-17 2016-02-10 天津药物研究院 一种制备lesinurad中间体1-萘基三唑硫酮的方法
CN104341363B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370842B (zh) * 2014-10-27 2016-07-13 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104327000B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104326993B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341361B (zh) * 2014-10-27 2017-01-11 张远强 一种腈基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104370841B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104326998B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104341362B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104311498B (zh) * 2014-10-27 2016-04-06 张远强 烷氧基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
EP3112334A1 (fr) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Procédé de fabrication de 1-cyclopropyl-naphthalènes
CN104987311A (zh) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯
CN105017168A (zh) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
CN105153056A (zh) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
WO2017036884A1 (fr) 2015-08-28 2017-03-09 Sandoz Ag Co-cristal de lésinurad, forme libre/ester éthylique de lésinurad
CN105566237B (zh) * 2016-03-01 2018-05-18 山东大学 一种治疗痛风的三唑巯乙酸类化合物的制备方法
EP3473617B1 (fr) * 2016-06-17 2022-09-07 Medshine Discovery Inc. Composé halogéné et ses isomères chiraux axial
EP3281941B1 (fr) 2016-08-11 2019-07-24 Zentiva K.S. Procédé de préparation d'acide 2-(5-bromo-4-(1-cyclopropylnaphtalén-4-yl)-4h-1,2,4-triazol-3-ythio) acétique
EP3372592A1 (fr) 2017-03-07 2018-09-12 Zentiva, k.s. Formes solides de sels d'amines de lesinurad
US10351537B2 (en) * 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (fr) 2017-04-19 2018-05-02 Química Sintética, S.A. Forme amorphe de lésinurad et ses procédés de préparation
CN108947919B (zh) 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
WO2019001325A1 (fr) * 2017-06-28 2019-01-03 苏州科睿思制药有限公司 Forme cristalline xv de lésinurad et son procédé de préparation
EP3498697A1 (fr) 2017-12-12 2019-06-19 Química Sintética, S.A. Nouveaux sels et polymorphes de lesinurad
WO2022249788A1 (fr) 2021-05-28 2022-12-01 住友化学株式会社 Procédé de production de bromure de cycloalkyle

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009A (en) * 1841-03-18 Improvement in machines for boring war-rockets
US2006A (en) * 1841-03-16 Clamp for crimping leather
US226186A (en) 1880-04-06 Car-coupling
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
JPS5641637B2 (fr) 1973-11-26 1981-09-29
US6832996B2 (en) * 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
JPH07215940A (ja) 1994-01-27 1995-08-15 Torii Yakuhin Kk 抗ウイルス活性を有する化合物
US6245817B1 (en) * 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
WO1998035957A1 (fr) 1997-02-14 1998-08-20 Bayer Corporation Derives amides actifs comme antagonistes selectifs du recepteur du neuropeptide y
JPH10243033A (ja) * 1997-02-28 1998-09-11 Oki Electric Ind Co Ltd 復調装置
ES2361146T3 (es) * 1998-03-27 2011-06-14 Janssen Pharmaceutica Nv Derivados de la piramidina inhibitatoria de vih.
CN1178941C (zh) 1998-11-12 2004-12-08 纽罗克里恩生物科学有限公司 Crf受体拮抗剂以及与其有关的方法
WO2000037471A1 (fr) * 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: ligands pour recepteurs cerebraux gaba
CA2353961A1 (fr) * 1998-12-25 2000-07-06 Shionogi & Co., Ltd. Composes heterocycliques aromatiques possedant des activites inhibitrices de l'integrase du vih
US6593077B2 (en) * 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
MXPA03007883A (es) 2001-03-02 2003-12-04 Smithkline Beecham Corp Benzofenonas como inhibidores de transcriptasa inversa.
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
EP1505968A1 (fr) 2002-05-13 2005-02-16 Eli Lilly And Company Composes multicycliques que l'on utilise comme antagonistes de l'hormone de concentration de melanine dans le traitement de l'obesite et du diabete
CN1697650B (zh) 2002-08-23 2010-11-10 阿迪亚生命科学公司 非核苷类逆转录酶抑制剂
US7642277B2 (en) * 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
DE602004031641D1 (de) 2003-09-25 2011-04-14 Janssen Pharmaceutica Nv Die replikation von hiv hemmende purinderivate
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
US7517998B2 (en) 2004-06-01 2009-04-14 Boehringer Ingelheim International Gmbh Non nucleoside reverse transcriptase inhibitors
WO2007050087A1 (fr) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. Acides N[S(4-aryltriazol-3-yl)α-mercaptoacétyl]-p-aminobenzoïques EN TANT QU'INHIBITEURS DE TRANSCRIPTASE INVERSE DE VIH
EA015846B1 (ru) 2004-08-25 2011-12-30 Ардеа Байосайенсиз, Инк. 2-[5-бром-4-(4-циклопропилнафталин-1-ил)-4н-[1,2,4]триазол-3-илсульфанил]уксусная кислота и ее метиловый эфир
NZ601774A (en) * 2007-11-27 2013-07-26 Ardea Biosciences Inc Substituted diazole and triazole compounds and compositions and methods of use
AR073964A1 (es) 2008-10-24 2010-12-15 Ardea Biosciences Inc Composiciones que comprenden acido 4-(2-(5-bromo-4-(1-ciclopropilnaftalen -4-il) -4h- 1,2,4-triazol-3-il tio ) acetamido)-3-clorobenzoico y sus sales farmaceuticamente aceptables y metodos de preparacion y uso delos mismos
WO2010048592A1 (fr) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprenant l'acide 4-(2-(5-bromo-4-(1- cyclopropylnaphtalén-4-yl)-4h-1,2,4-triazol-3-ylthio)acétamido-3- chlorobenzoïque et ses sels de qualité pharmaceutique
TWM377707U (en) * 2009-09-16 2010-04-01 Nat Energy Technology Co Ltd Assembly of power supply

Also Published As

Publication number Publication date
ECSP077322A (es) 2007-04-26
US20150094284A1 (en) 2015-04-02
HK1133582A1 (en) 2010-04-01
US8946273B2 (en) 2015-02-03
IL181523A (en) 2013-12-31
WO2006026356A2 (fr) 2006-03-09
AU2005280130B2 (en) 2009-09-10
FR16C0031I2 (fr) 2017-03-31
BRPI0520870B8 (pt) 2021-05-25
EP2433633A1 (fr) 2012-03-28
EA015846B1 (ru) 2011-12-30
LTC2135608I2 (lt) 2017-07-25
DK2135608T3 (da) 2012-01-23
JP5457472B2 (ja) 2014-04-02
IL201546A (en) 2013-10-31
KR101241716B1 (ko) 2013-03-08
NZ581376A (en) 2011-05-27
US8481581B2 (en) 2013-07-09
CA2578068C (fr) 2011-08-09
US20120283301A1 (en) 2012-11-08
ME01512B (me) 2014-04-20
CY2016028I1 (el) 2016-12-14
BRPI0520870B1 (pt) 2020-11-10
SI2135608T1 (sl) 2012-03-30
AU2009217458A1 (en) 2009-10-15
BRPI0514630B8 (pt) 2021-05-25
CN101083987B (zh) 2011-01-26
CA2578068A1 (fr) 2006-03-09
ES2380604T3 (es) 2012-05-16
EP2135608A1 (fr) 2009-12-23
AU2009217458B2 (en) 2009-11-19
JP2012077088A (ja) 2012-04-19
NL300825I2 (fr) 2017-01-24
CN101817793A (zh) 2010-09-01
US20180002296A1 (en) 2018-01-04
CY2016028I2 (el) 2016-12-14
LTPA2016024I1 (lt) 2016-09-12
EP2135608B1 (fr) 2011-10-12
PL2135608T3 (pl) 2012-07-31
NZ553534A (en) 2010-10-29
US20100069645A1 (en) 2010-03-18
CN101083987A (zh) 2007-12-05
FR16C0031I1 (fr) 2016-09-23
AU2009217458A8 (en) 2009-10-29
EP2402011B1 (fr) 2012-11-14
SG185992A1 (en) 2012-12-28
US20110190491A1 (en) 2011-08-04
AU2005280130C1 (en) 2010-02-18
US20110313157A1 (en) 2011-12-22
EA200700488A1 (ru) 2007-08-31
IN2014CN03762A (fr) 2015-09-25
CY1112221T1 (el) 2015-12-09
US7947721B2 (en) 2011-05-24
CN101817793B (zh) 2014-01-08
IL181523A0 (en) 2007-07-04
IL219131A0 (en) 2012-06-28
PT2135608E (pt) 2012-01-13
US20100267724A2 (en) 2010-10-21
JP4952943B2 (ja) 2012-06-13
WO2006026356A3 (fr) 2006-08-10
KR20070054694A (ko) 2007-05-29
EP2135608B8 (fr) 2012-03-21
AU2005280130C9 (en) 2010-03-04
ES2374773T3 (es) 2012-02-21
EP1789039B1 (fr) 2012-01-11
HUS1600034I1 (hu) 2016-09-28
ATE540677T1 (de) 2012-01-15
US20100081827A1 (en) 2010-04-01
JP2008510828A (ja) 2008-04-10
EA200901186A1 (ru) 2010-04-30
EP2609917A1 (fr) 2013-07-03
US8252828B2 (en) 2012-08-28
SG155246A1 (en) 2009-09-30
MX2007002236A (es) 2007-07-09
EA014737B1 (ru) 2011-02-28
EP1789039A2 (fr) 2007-05-30
EP1789039A4 (fr) 2009-08-05
AU2005280130A1 (en) 2006-03-09
RS52632B (en) 2013-06-28
US20080176850A1 (en) 2008-07-24
EP2402011A1 (fr) 2012-01-04
BRPI0514630B1 (pt) 2020-09-15
US8003681B2 (en) 2011-08-23
BRPI0514630A (pt) 2008-06-17
HRP20130075T1 (hr) 2013-02-28
ATE528001T1 (de) 2011-10-15

Similar Documents

Publication Publication Date Title
LU93169I2 (fr) Lésinurad , ou un sel pharmaceutiquement acceptable de celui-ci
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
ATE494893T1 (de) Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmer
USD536756S1 (en) Ball
ATE336995T1 (de) Aminocyclohexenchinoline und ihre azaisosterischen analoga mit antibakterieller wirkung
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
IS2714B (is) Uppsöfnun í frumu á phosphomate hliðstæðum á HIV próteasa hindrandi efnasamböndum
WO2005032488A3 (fr) Sulfonylurees 2,4-dioxo-3-quinazolinylaryl
ATE373005T1 (de) Thienopyrrole als antivirale mittel
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
ATE414092T1 (de) Phosphoindole als hiv-inhibitoren
RU2007122284A (ru) Предотвращениеи вертикальных инфекций, вызываемых эндопаразитами
DE50112436D1 (de) Notaus-tastensystem
AU2003243765A8 (en) 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors
DE602006013953D1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl-y-aminopropyl-azalide mit antimalaria-aktivität
USD497998S1 (en) Pear-shaped bath sponge massager
DE602004030265D1 (de) Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin
ES2195905T3 (es) Compuestos de tiofen-etil-tiourea y su uso en el tratamiento de sida.
CY1111067T1 (el) Χρηση της ν-(διβενζ (β,f) οξεπιν-10-υλμεθυλ) -ν-μεθυλ-ν-προπ-2-υνυλαμινης (omigapil) στην προληψη και/ή την θεραπεια της μυϊκης δυστροφiας
USD475098S1 (en) Craft kit construction component—leg form
AU2003265223A1 (en) Mappicine analogs, methods of inhibiting retroviral reverse transcriptase and methods of treating retroviruses
RU2004124585A (ru) Способ пластики вращательной манжеты плеча
DE50301462D1 (de) (Tief)Kühltruhe
RU2001127549A (ru) Монолитный каблук